- $16.66m
- $13.62m
- $107.40m
- 56
- 95
- 69
- 85
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 4.93 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.56 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 1.98 | ||
Price to Sales | 0.19 | ||
EV to EBITDA | 2.05 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -3.18% | ||
Return on Equity | -38.18% | ||
Operating Margin | -1.53% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 7.32 | 27.63 | 65.63 | 96.67 | 107.4 | 81.33 | 78.22 | 96.56% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
Directors
- Joshua Disbrow CHM (46)
- Mark Oki CFO (52)
- Jerry McLaughlin DRC (53)
- Gary Cantrell IND (66)
- Carl Dockery IND (58)
- John Donofrio IND (53)
- Beth Hecht IND (57)
- Michael Macaluso IND (69)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 8th, 2015
- Public Since
- October 20th, 2017
- No. of Shareholders
- 190
- No. of Employees
- 150
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,972,327
- Address
- 7900 E. Union Avenue, Suite 920, DENVER, 80237
- Web
- https://aytubio.com/
- Phone
- +1 7204376580
- Auditors
- Plante & Moran PLLC
Upcoming Events for AYTU
Q4 2024 Aytu Biopharma Inc Earnings Release
Q1 2025 Aytu Biopharma Inc Earnings Release
Similar to AYTU
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
As of Today at 19:29 UTC, shares in Aytu Biopharma are trading at $2.91. This share price information is delayed by 15 minutes.
Shares in Aytu Biopharma last closed at $2.91 and the price had moved by +73.21% over the past 365 days. In terms of relative price strength the Aytu Biopharma share price has outperformed the S&P500 Index by +37.83% over the past year.
The overall consensus recommendation for Aytu Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aytu Biopharma does not currently pay a dividend.
Aytu Biopharma does not currently pay a dividend.
Aytu Biopharma does not currently pay a dividend.
To buy shares in Aytu Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.91, shares in Aytu Biopharma had a market capitalisation of $17.38m.
Here are the trading details for Aytu Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AYTU
Based on an overall assessment of its quality, value and momentum Aytu Biopharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aytu Biopharma is $8.00. That is 174.91% above the last closing price of $2.91.
Analysts covering Aytu Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.49 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aytu Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -12.62%.
As of the last closing price of $2.91, shares in Aytu Biopharma were trading +4.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aytu Biopharma PE ratio based on its reported earnings over the past 12 months is 4.93. The shares last closed at $2.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aytu Biopharma's management team is headed by:
- Joshua Disbrow - CHM
- Mark Oki - CFO
- Jerry McLaughlin - DRC
- Gary Cantrell - IND
- Carl Dockery - IND
- John Donofrio - IND
- Beth Hecht - IND
- Michael Macaluso - IND